Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer - PubMed
21 hours ago
- #Metformin
- #γδ T cells
- #TNBC immunotherapy
- Metformin enhances γδ T cell therapy in triple-negative breast cancer (TNBC) by improving cytotoxicity, proliferation, and cytokine production.
- It reduces exhaustion markers in γδ T cells while suppressing oxidative phosphorylation (OXPHOS) and glycolysis in cancer cells via AMPK-HIF-1α signaling.
- Metformin upregulates stress ligands on tumor cells, enhancing immune recognition, and restores γδ T cell function in chemoresistant models.
- Clinical data associate high AMPK activity and increased γδ T cell infiltration with improved survival in TNBC patients.
- The study supports metformin as a combinatory agent in immunotherapy, remodeling immunometabolism and boosting tumor immunogenicity for TNBC treatment.